Pulnovo Medical used a busy week of scientific and investor outreach to reinforce its focus on pulmonary artery denervation (PADN) for pulmonary hypertension and heart failure. The company aligned its messaging with World Pulmonary Hypertension Day under the theme “Hope in Every Trial,” positioning PADN as an original innovation and a “bridge of hope” between scientific rigor and patient outcomes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pulnovo hosted and concluded a global PADN symposium tied to the awareness day, featuring more than 10 international experts, live case demonstrations, and interactive discussions. The event highlighted the full PADN workflow, emphasized safety and feasibility, and stressed the need to refine patient selection and standardize procedures through multi‑center collaboration.
The company is also preparing a presence at Heart Failure 2026 in Barcelona, where it plans to showcase its pulmonary vascular intervention technology on a global stage. Pulnovo’s communications pointed to recent milestones, including EU‑MDR CE certification and an FDA IDE trial enrolling patients in the U.S. and Europe, underscoring regulatory and clinical progress.
At the congress, Pulnovo will feature academic content on device therapy for pulmonary hypertension due to left heart disease and conduct a live case walkthrough in pulmonary arterial hypertension. This scientific focus is aimed at strengthening relationships with cardiologists and key opinion leaders, which could support future adoption and trial collaborations.
In parallel, Pulnovo stepped up business development efforts at the 26th Bio€quity Europe conference in Prague, where its Senior Business Development Director presented in a late‑breaking MedTech innovation track. The company engaged with global investors and industry leaders, emphasizing PADN’s potential to redefine standards of care and its strategy to navigate global regulatory pathways efficiently.
Pulnovo highlighted “strategic dialogues” at Bio€quity that it hopes will translate into long‑term partnerships across the European life sciences ecosystem. These activities suggest a coordinated push to expand its international footprint, build alliances, and prepare for commercialization, while continued clinical and regulatory progress will likely be key to shaping its future prospects.